We Claim:

1. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) from about 15% to about 25% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:



;

b) from about 35% to about 45% w/w of sofosbuvir characterized by XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 10.4 and 20.8, wherein the sofosbuvir is substantially crystalline having the formula:



c) from about 30% to about 40% w/w of microcrystalline cellulose;

d) from about 1% to about 5% w/w of croscarmellose sodium; and

e) from about 0.5% to about 2.5% w/w of magnesium stearate.

2. The pharmaceutical composition of claim 60, comprising about 40% w/w of sofosbuvir.

3. The pharmaceutical composition of claim 60, comprising about 20% w/w of the solid dispersion.

4. The pharmaceutical composition of claim 60, comprising about 35.5% w/w of microcrystalline cellulose.

5. The pharmaceutical composition of claim 60, comprising about 3% w/w of croscarmellose sodium.

6. The pharmaceutical composition of claim 60, comprising about 1.5% w/w of magnesium stearate.

7. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) about 20% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:


;

b) about 40% w/w of sofosbuvir characterized by XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 10.4 and 20.8, wherein the sofosbuvir is substantially crystalline having the formula:



;

c) about 35.5% w/w of microcrystalline cellulose;

d) about 3% w/w of croscarmellose sodium; and

e) about 1.5% w/w of magnesium stearate.

8. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) about 200 mg of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:



;

b) about 400 mg of sofosbuvir characterized by XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 10.4 and 20.8, wherein the sofosbuvir is substantially crystalline having the formula:



;

c) about 355 mg of microcrystalline cellulose;

d) about 30 mg of croscarmellose sodium; and

e) about 15 mg of magnesium stearate.

9. The pharmaceutical composition of claim 67, wherein the tablet comprises a film coating.

10. The pharmaceutical composition of claim 68, wherein the film coating is a polyvinylalcohol-based coating.

Dated this 11th day of March, 2016

NAMRATA CHADHA
OF K&S PARTNERS
AGENT FOR THE APPLICANT(S)
IN/PA-1904